

Sajeve Samuel Thomas

Contact Information:

628-600-3589

expert@praxisid.com

www.praxismedexperts.com



Medical Oncologist Locum

St Vincent Billings Montana
11/2024 – present

Director of Solid Tumor Cellular Therapy TIL –Cutaneous/Sarcomas

- Orlando Health Cancer Institute at Orlando Health
- 8/2022 – Present
- Section Lead Cutaneous/Connective Tissue Malignancy Section 13 years
- 12 years' experience with Gastrointestinal Malignancies
- Championed TIL, OHCI is a TIL ATC
- TIL Treatment Metastatic Melanoma x 7 years
- TIL EAP 1st Global to open and most enrolled/treated 30+ patients
- OHCI is one of 30 sites across the country to deliver TIL commercially.
- Procedures with TVEC, pIL-12/RE, TLR9 agonist, Viral therapies Herpes, Polio.
- Solid Tumor Cellular Therapy TIL or TCR T Cell Clinical Trials with Iovance, Tscan, Tbio, Obsidian, Adaptaimmune treated Gyn, GI malignancies, \$6-7 million in research grants
- DWG Section Lead for Cutaneous/Sarcoma - management a large team of research coordinators, data managers, regulatory coordinators, research pharmacist
- Melanoma/Sarcoma Tumor board biweekly 13 years
- Gastrointestinal and Colorectal Tumor board weekly x 12 years
- Principal Investigator Phase I/II/III clinical trials using bispecifics, mRNA, cytokines, cellular therapies, targeted therapies, immunotherapies, combination chemotherapies
- Speaker – Grand Grounds for OHCI, Grand Rounds University of Miami Dermatology, Annual Fellow's conference Melanoma, Soft Tissue Sarcoma, Bone Sarcomas, Journal Club
- 2024 ASCO Oral Abstract Melanoma Presenter – Iovance Phase II TIL/Pembro

Medical Oncology Blog site www.MedOncMD.com

To bring awareness to actively enrolling clinical trials and distill medical oncology information to patients, caregivers, and healthcare providers

www.medoncmd.com

Medical Oncologist –Cutaneous/Sarcomas/Gastrointestinal Malignancies

Section Lead Cutaneous/Connective Tissue Malignancy Section
Orlando Health Cancer Institute at Orlando Health
8/2011 – Present

Clinical Investigator – Cutaneous/Sarcomas/Gastrointestinal Malignancies

Orlando Health Cancer Institute at Orlando Health
Phase I/II/III clinical trials
2014 - Present

Clinical Investigator – Melanoma/GI Section

MD Anderson Cancer Center Orlando
8/2011 – 2014

Medical Oncology/Hematology Expert Witness

2013 – Present – mostly causation opinions, few standard of care opinions

Foundation One Genomic Tumor Board (National and International)

Medical Oncology consultant
2018-2021

Medical Oncology Consultant – Speaker

BMS, Merck, Ipsen, Novartis, Array, Amgen, Genentech, Springwork, Natera
Advisory boards with Merck, Novartis, BMS, Pfizer
2013 – Present

UCF College of Medicine Assistant Professor

University of Central Florida, Orlando
10/2011 – Present

FSU College of Medicine Assistant Professor

University of Central Florida, Orlando
10/2011 – Present

Chief Fellow - Hematology/Oncology

University of Florida, Gainesville, Florida
7/2010 – 6/2011

Board Review Coordinator Hematology-Oncology

University of Florida, Gainesville, Florida
7/2009– 6/2011

Hematology/Oncology Fellowship

University of Florida, Gainesville, Florida
7/2008 – 6/2011

Internal Medicine Residency

University of South Florida IM, Tampa, Florida
7/2005 – 6/2008

Medical Education

University of Florida College of Medicine, Gainesville, Florida
Medical Doctorate
7/2001 - 6/2005

Undergraduate

University of South Florida, Tampa, FL
B.A. Computer Science
8/1997 - 6/2001


Dual Enrollment

Broward Community College, Davie, FL
1/1997 - 5/1997

Enrollment at our Site 2022-2023 – Top enrollment for Melanoma and GI

Disease Working Group		Treatment		Early Phase Treatment		Radiation Treatment		Treatment Totals		Non-Treatment		Biorepository		Disease Working Group		All Facilities	
		2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023			2022	2023
Breast		2	4	---	---	---	16	2	20	14	11	1	4	Breast	17	35	
Gastrointestinal		5	7	2	7	1	---	8	14	6	3	2	4	Gastrointestinal	16	21	
Genitourinary		1	1	---	---	---	---	1	1	29	15	---	---	Genitourinary	30	16	
Gynecology		---	2	---	---	---	---	---	2	---	---	---	---	Gynecology	---	2	
Head-Neck		13	7	---	---	1	---	14	8	6	14	1	4	Head-Neck	21	26	
Hematology		4	---	---	---	---	1	4	---	1	---	1	---	Hematology	6	---	
Melanoma		35	26	2	19	---	---	37	45	16	14	---	2	Melanoma	53	61	
Neurological		2	1	---	---	---	---	2	1	25	12	1	---	Neurological	28	13	
Obsidian		---	---	---	---	---	---	---	---	---	---	---	6	Obsidian	---	6	
Other		---	---	---	---	---	---	---	---	5	43	---	---	Other	5	43	
Sarcoma		---	3	---	---	---	---	3	---	---	---	---	---	Sarcoma	---	3	
Thoracic		2	1	---	2	---	---	2	3	36	48	4	3	Thoracic	42	54	
Totals		64	52	4	28	2	17	70	97	138	160	10	23	Totals	218	280	

Orlando Health Cancer Institute is one of the initial 30 ATC Authorized Treatment Centers to Deliver TIL to Metastatic Melanoma patients.



School Awards & Membership in Honorary/Professional Societies

- NANET - member
- NSABP - member
- American Society of Hematology - Member
- American Society of Clinical Oncology - Member

American College of Physicians
Outstanding Resident Award USF
Residents and Fellows of Indian Origin, Tampa Bay Chapter
Golden Key National Honor Society

Certification/Licensure

Diagnosis and Management of Coagulation Disorders 12/04/08
Fully licensed in state of Florida 7/08
ACLS Certified 7/07

Examinations

Hematology and Oncology Board Certified 11/2012
Hematology In-Service Exam 2/2010 – **90th Percentile**
Oncology In-Service Exam 3/2010 – **90th Percentile**
American Board of Internal Medicine 8/08 – Passed / Board Certified
USMLE Step 3 8/2007
USMLE Step 2 CS (Clinical Skills) 1/2005
USMLE Step 2 CK (Clinical Knowledge) 11/2004
USMLE Step 1 6/2003

Awards/Accomplishments

Patient KIOSK Improved Perception Waiting- 2014
Clinical scribe – piloted first with improved clinic efficiency, notes, staging, orders
Narrative templates – improved pt oncology summary, billing, coding, presentation
ASCO Conquer Cancer Mentor Award 6-7/2012
Pfizer Drug Development Simulation – Program Manager for the Winning Team
Hem/Onc Pharmacology Jeopardy – 1st Place
Outstanding Resident Award – Distinction given to only 10% of our class
Dean's List Four Consecutive Years
Engineering Dean's List
USF Scholar Award by USF Honor's Program
Golden Key National Honor Society Scholar

Publications

Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
• JCO 2021
Efficacy and safety of lifileucel a one-time autologous tumor infiltrating lymphocyte TIL cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies,: pooled analysis of consecutive cohorts C144-01
• Journal of Immunotherapy Cancer 2022
Individualized neoantigen therapy mRNA-4157 V940 plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma Keynote 942: a randomized phase 2b study
• Lancet 2024
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
• J Immunotherapy Cancer 2021
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab ovitecan, for the Treatment of Diverse Metastatic Solid Tumor.
• Clin Cancer Res 2015 Sep 1;21(17):3870-8 PMID: 25944802
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
• Clin Cancer Res 2020 May. PMID: 31980466
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
• J Immunother Cancer 2016 Aug PMID: 27532019
Melanoma/Sarcoma Rotational Curriculum for MDACCO Fellowship Program
"Institutional Review In The Treatment of Bladder/Upper Urinary Tract Malignancies"
Retrospective review
"Updated Review In the Management of Patients With Metastatic Brain Disease" Published in *Current Oncology*

Case Report: "Unique Polymorphism of Low Cytochrome b5 Expression in a Patient With Methemoglobinemia" submitted to the Journal of Clinical Pharmacology

Volunteer Experience

3/2012 – Metro Church Health Fair – Panelist
7/2009 – 6/2010 Hematology/Oncology Board Review Coordinator
7/2008 – 6/2010 Medical Student Preceptor for Hematology/Oncology Education
8/2001 - 5/2005 Equal Access Clinic – Indigent Care Clinic
8/1999 - 5/2001 Golden Key National Honor Society Webmaster
8/1998 - 5/1999 Minority Pre-Professional Science Society – Vice President
1/1996 - 5/1997 IPC Church of God - Youth Coordinator and Pianist

Research

Principal Investigator

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Principal Investigator

OMS-I103-- The Pisces Study: A Multicenter phase 2, open-label trial of Intratumoral Tavokinogene Telseplasmid (tavo, PIL-12) plus Electroporation in combination with intravenous Pembrolizumab in patients with stage III/IV Melanoma who are progressing on either Pembrolizumab or Nivolumab treatment

Principal Investigator

C-144-01- A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

Principal Investigator

IOV-COM-202- A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Principal Investigator

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 238)

Principal Investigator

CA209915- A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 915)

Principal Investigator

CL-CA-P01-Phase III, Randomized, Double-Blind, Multicenter Trial Of Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells (NBS20) Vs. Autologous Peripheral Blood Mononuclear Cell Control (MC), Both Coadministered With Adjuvant GM-CSF, For The Treatment Of Patients With Metastatic Melanoma

Principal Investigator

CA017-055- A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated

Principal Investigator

2125-MEL-301- A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Principal Investigator

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-

CTLA-4 Therapy.

Principal Investigator

CA209218 - Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Subjects with Unresectable or Metastatic Melanoma

Principal Investigator

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivolumab clinical Trial Evaluation 238)

Principal Investigator

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

Principal Investigator

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

Principal Investigator

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Principal Investigator

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Principal Investigator

LX1606-303: A Phase 3, Randomized, Placebo-controlled, Multicenter, Doubleblind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Principal Investigator

NSABP MPR-1 - NSABP Patient Registry and Biospecimen Profiling Repository

Principal Investigator

STX0112 - Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres,™ microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study

Principal Investigator

BT-CL-PGG-CRC1031 - A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbix®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Principal Investigator

IMMU-130-02- A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer

Principal Investigator

GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen

Principal Investigator

IMMU-132-01 - A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Principal Investigator

NSABP FC-7 - A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

Sub Investigator

PACE Clinical trial RCT using Bone Marrow Stem Cells in Patients with Severe PVD
Bone marrow Harvest

Sub Investigator

050012: A Phase I/II Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients with Solid Tumors

Sub Investigator

CA184-338 - A MULTI-SITE RETROSPECTIVE OBSERVATIONAL STUDY OF US PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA RECEIVING IPILIMUMAB (YERVOY®) AS FIRST-LINE THERAPY

Sub Investigator

2009-0288 - Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients

Sub Investigator

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.

Sub Investigator

TPU-TAS-102-301 - RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES

Principal Investigator

Cooperative group study - SWOG Study Phase III Prospective RCT comparison of Octreotide plus Interferon alpha vs Octreotide plus Bevacizumab in advanced poor prognosis carcinoid patients. 5/2012

Principal Investigator

ET743-SAR-3007 - "A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma". Janssen Research and Development LLC

Sub Investigator - Bone Marrow Harvest

AMORCYTE PreSERVE A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction.

Sub Investigator

CA184-240 - A Single Arm Open-Label Phase II Study of Vemurafenib Followed by a Continuous Administration of Ipilimumab in Subjects with Previously Untreated V600 BRAF Mutated Advanced Melanoma

Sub Investigator

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

Sub Investigator

ECOG E1609- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma. Eastern Cooperative

Oncology Group

Sub Investigator

SWOG S1005- A Phase II Study of MK-2206 (NSC-749607) as a Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer. SWOG

Sub Investigator

NCCTG N0949- Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer. North Central Cancer Treatment Group

Sub Investigator

RTOG 0848 - A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. RTOG

Sub Investigator

C80702 - A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. Southwest Oncology Group

Sub Investigator

IMCL CP15-0806: A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRalpha Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue. ImClone Systems Inc.

Sub Investigator

BIOVEX 005A- Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIB, IIIC and IV Disease. BIOVEX

Presentations

Core Lecture Speaker – Malignant Melanoma 2011- Present

Core Lecture Speaker – Neuroendocrine Malignancies 2012 – Present

Core Lecture Speaker – Bone sarcomas 2014 – Present

Core Lecture Speaker – Soft Tissue sarcomas 2014 - Present

NCAN Speaker "Medical Management of NET disease" 3/2015

CNET Speaker "NET associated Diarrhea" 8/2014

CNET Speaker "Medical Management of Pancreas and Bowel NET" 8/2013

Health Central "Skin Malignancies" 12/2013

Grand Rounds at MDACCO "Current Management of Neuroendocrine Tumors" 11/2012

Journal Club Anti PDI and Anti PDI ligand Phase I studies from NEJM 6/2012 MDACCO

Grand Rounds at MDACCO "Current Update in the Management of Melanoma" 9/2011

Metastatic Breast Cancer 4/2011

Journal Club "JCO 2010 Paper on MSI in Colon Cancer and Adjuvant Therapy" 5/2011

Testicular Malignancies

Sarcoma

CNS Malignancies

Bladder Cancer

Metastatic Colorectal Cancer

CRC Peritoneal Carcinomatosis

NSCLC

Journal Club: Brite Registry Data With Use of Bev Beyond 1st Progression

Journal Club: HRPC Phase II with Samarium and Chemotherapy

Medical Residents/Students/PA Lectures

Lymphomas, Acute Leukemias, Chronic Leukemias, Plasma cell Dyscrasias, BM Failure Syndromes, Myeloproliferative Disorders, Lung Cancer, Anemia, NF, BMT, Leukocytosis, Peripheral Smears, Colon, Lung, GI, GU, Melanoma/Sarcoma, Head/Neck

Board Review:

ASCO-SEP, ASH-SAP, JCO Clinical Diagnosis, MD Anderson BR, HematoPath Lab, NCCN

CME, ASCO VM, Jeopardy

References

Dan Buchholz- CEO UFHCC Orlando Health 407-247-6192
Omar Kayaleh – GI Med Onc Section Chief 407-716-2275
Debu Bose – Chief of GI Surgical Oncology, Leader of Pancreas Center 407-462-5374
Patrick Kelly – Radiation Oncology for GI Section 407-766-6307
Carmen Allegra Chief of the Hematology Oncology Division - 352-219-1989

Conferences

Melanoma Symposium New York 2015
ASCO Chicago 2010, 2011, 2012, 2015
Neuroendocrine Tumors Ottawa 2012
Sarcoma and GIST Milan 2012
GI ASCO Symposium San Francisco 2012, 2013, 2014
Melanoma Symposium Tampa 2011
NANET Conference San Diego 2012, Charleston 2013, Tennessee 2014
NCCN Hollywood 2013

Hobbies & Interests

Piano, basketball, ultimate frisbee, finance, real estate

Board Review

2011-2012 MDAnderson HemOnc Fellow Board Review

Aug Breast
Sept Lung, HNC
Oct Melanoma/Sarcoma, CDO
Nov GU I/II
Dec GI I/II
Jan BioStatistics
Feb CNS, CDO
March Gyn I/II
April Pharmacology I/II
May Molecular Biology, CDO
June Epidemiology/Supportive Care, BMT

2010-2011 University of Florida Fellow Board Review

Breast Cancer Cases with Dr Heldermon (Onc)
BMT Jeopardy
Clinical Diagnosis in Oncology (JCO)
HematoPath Lab Acute Leukemias
Hematology Meds Part II with Dr Zumberg (Hem)
IMER Mantle Cell Lymphoma
Hemolytic Anemia with Dr Zumberg (Hem)
Transfusion Jeopardy
IMER Ovarian Cancer
Molecular Biology/Genetics Jeopardy
HematoPath Lab Low Grade Lymphomas
Normal B Cell Development with Dr Winters (Immuno)
IMER Prostate Cancer with Dr Blake
"Skin Manifestations with Internal Malignancies" with Dr Mitchell (Derm)
Anemia Jeopardy (Dec 2010)
IMER MM and SCT (Jan 2011)
Jay Lynch's Re-hASH (Lymphoma) (Jan 2011)
Bleeding Disorder Jeopardy (Jan 2011)
HematoPath Lab Aggressive Lymphomas (Jan 2011)

Clinical Diagnosis in Oncology (Feb 2011)
"I have AIDS and I'm Pregnant" Jeopardy (Feb 2011)
IMER CLL (Feb 2011)
Gyn Malignancies/Testicular Jeopardy (March 2011)
IMER CML (March 2011)
Breast Ca Jeopardy (April 2011)
"Rare/Uncommon Malignancies" Jeopardy (May 2011)

2009-2010 University of Florida Fellow Board Review

2009

Peripheral Smears: Red Cells/Thrombocytopenia Part I
Peripheral Smears: Red Cells/Thrombocytopenia Part II
Peripheral Smears: Malignant Hematology with Graham
ASCO/NCCN Cetuximab Reaction Iman/Sajeve
Hemophilia/Hematology Part II Dr Zumberg
ASH - MDS with Cogle
Oncotype Dx with Karen Daily
ASH - Lymphoproliferative disorders, MJ/Lynch/Dang
Carcinogenesis/Molecular Biology Part I- Bennett
Carcinogenesis/Molecular Biology Part II- Bennett
IMER DLBCL Dr Flynn
ASH - Hemolytic Anemia/Dr Zumberg
Dang - Informal talk on Mantle Cell and T cell Lymphoma
Common Skin Infections in Immunocompromized Patients with Dermatology Dr Mitchell
Thalassemia/Sickle cel q's with Dr Lottenberg
IMER MDS
IMER: Multiple Myeloma
ASH-SAP Transfusion Medicine
Carcinogenesis/Molecular Biology Part III - Bennett Part III
ASH-SAP Plasma cell dyscrasia with Dr Moreb
MD Anderson Review Benign Hematology
Hematopath Lab Acute Leukemia
ASH-SAP Myeloid Disorders with Fletcher
MD Anderson Review Malignant Hematology
ASH-SAP Hemostasis/Thrombosis

2010

ASH-SAP Iron Metabolism, Acquired Anemia
IMER: Breast Cancer
IMER: Melanoma
Hematopath Lab Benign LAD, Low Grade Lymphoma
Hematopath Lab Aggressive Lymphomas
IMER: Renal Cell Carcinoma
Dr Lynch "Best of ASH Lymphoma"
IMER CML
ASCO SEP Breast Cancer QA
Hematopath MDS subtypes/Myeloproliferative
BAC Julia
ASCO SEP Sarcoma/Melanoma
HematoPath Lab Plasma cells/Masto/Eosino/etc Graham
ASCO SEP GynOnc with MJ
Dr Grosbach's "Potpourri of Blood Smears"
GU ASCO-SEP Jeopardy
Diagnosis in Oncology JCO
Dr Gopalan's "Carcinoma of Unknown Primary"
Dr Siddiqui's "Rare Tumors"
Dr Kim Liver Transplant Hepatobiliary Malignancies
Dr Pennypacker End of Life Care
Head/Neck ASCO-SEP Jeopardy